Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FKKD5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,763
Award facts
- Contract value 100% obligated
- $16,762.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,762.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. The delivery order, issued on November 24, 2025, with an ultimate completion date of December 16, 2025, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, that positions the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations globally through December 31, 2036.
The PPV-G GEN V program represents part of a broader $30.3 billion federal acquisition strategy designed to streamline pharmaceutical supply chain operations across military healthcare facilities worldwide. Under this contract vehicle, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The delivery order for Nexplanon implants reflects the contractor's established performance in fulfilling the diverse and specialized pharmaceutical requirements of the Department of Defense medical system, with the company demonstrating substantial contracting activity through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DR26FKKD5?
SPE2DR26FKKD5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26FKKD5 worth?
The government has obligated $16,763 on SPE2DR26FKKD5.
Is contract SPE2DR26FKKD5 an order under another contract?
Yes. SPE2DR26FKKD5 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKD5 competed?
The extent of competition for SPE2DR26FKKD5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award